Recent Finacing
Recent Raise
GRAIL develops blood‑based methylation sequencing liquid‑biopsy tests that detect circulating tumor DNA across many cancer types, infer tissue‑of‑origin, and leverage large sequencing databases and machine‑learning for population‑scale screening.
